false
Catalog
Strategies for Success: Using Long-Acting Injectab ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
This document is a summary of a webinar titled "Strategies for Success: Using Long-Acting Injectable Medications" which was part of an initiative by the American Psychiatric Association (APA) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The webinar discussed the benefits and best practices for using long-acting injectable medications in the treatment of serious mental illness. <br /><br />The webinar emphasized that long-acting injectable medications can be superior to oral antipsychotic medications in terms of symptom reduction, decreased re-hospitalization rates, and lower mortality rates. The use of long-acting injectables is recommended for patients with a history of medication non-adherence, co-morbid substance use, difficulty maintaining medication regimens, new-onset psychosis, or patient preference.<br /><br />The webinar also provided information on different long-acting injectable medications currently available on the market, including their dosing and administration instructions. It discussed the importance of understanding the pharmacokinetics of these medications to ensure optimal therapeutic outcomes. <br /><br />The webinar also highlighted some common barriers to using long-acting injectables, such as resistance from healthcare insurance companies, patient fears, and physician reluctance. Strategies for addressing these barriers were provided, including working with insurance companies to get coverage, educating patients about the benefits and control offered by long-acting injectables, and familiarizing physicians with the medications through education and training. <br /><br />Overall, the webinar emphasized the importance of long-acting injectable medications in improving outcomes for individuals with serious mental illness and provided guidance on their optimal use.
Keywords
Long-Acting Injectable Medications
Strategies for Success
American Psychiatric Association
Substance Abuse and Mental Health Services Administration
Serious Mental Illness
Symptom Reduction
Medication Non-Adherence
Pharmacokinetics
Barriers to Usage
Optimal Therapeutic Outcomes
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English